{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE270nnn/GSE270357/"]},"type":"primary"},"statusCodeValue":200,"statusCode":"OK"}],"scores":null,"additional":{"omics_type":["Transcriptomics"],"species":["Homo sapiens"],"gds_type":["Expression profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE270357"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"Transcriptome sequencing of palmitic acid-treated HepG2 cells upon intervention of curcumin or curcumin-copper complex","description":"Globally, non-alcoholic fatty liver disease (NAFLD) poses a major risk to human health. The natural polyphenol curcumin (Cur) can act as a copper (Cu) transporter in a Cur-Cu complex for enhanced Cu cell loading, but the effects of such a complex on NAFLD remain unclear. HepG2 liver cancer cells were treated with palmitic acid (PA) to create an in-vitro NAFLD model. And the purpose of this study was to investigate the impacts of a Cur- Cu complex on this model, and its potential mechanisms and targets in the reduction of fatty-acid accumulation in HepG2 cells.","dates":{"publication":"2026/06/19"},"accession":"GSE270357","cross_references":{"GSM":["GSM8340250","GSM8340242","GSM8340243","GSM8340244","GSM8340245","GSM8340246","GSM8340247","GSM8340248","GSM8340249"],"GPL":["34284"],"GSE":["270357"],"taxon":["Homo sapiens"]}}